Skip to content
ESPT
MARKETS / BALCAO / Health care / Pharmaceuticals / PCYN
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Procyon Corp. PCYN

14 fiscal years on record · USD · FY2023 reported · SEC filings only
$5.0M
▲ 6.4% YoY
$-341,140
$-125,163

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Procyon Corporation ("Procyon" or the "Company") consolidates the operations of Procyon with AMERX® Health Care Corporation("AMERX") and Sirius Medical Supply, Inc. ("Sirius"), its wholly-owned subsidiaries, for financial purposes. AMERX® develops and markets proprietary medical products used in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation and other skin problems. Sirius no longer has any material operations. AMERX spent approximately $30,100 towards research and development efforts over the past fiscal year. We believe this reimbursement code is beneficial to AMERX's business, allowing customers on Medicare to seek coverage for use of these products.

Written from the business description in Procyon Corporation's annual report to the U.S. Securities and Exchange Commission, filed 25 October 2024. Every sentence was checked against that document before publication.

Growth

USD 5.0M
Revenue, FY2023 · full 14-year series below
Revenue $M Net income $M
FY2023 · Revenue 5.0 · Net income -0.3
2M4M
201020132016201920222023
Compound annual growth
+1.8%
+3.5%
+5.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.5% a year over the five years to FY2023.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−7 cents
lost on every revenue dollar
Operating margin Net margin
FY2023 · Operating -4.6% · Net -6.8%
5%10%-5%-10%
201020162023
ROE
FY2023 · ROE -13.9%
10%20%-5%-10%
201020162023
Three returns, three denominators.
Gross margin78.1%
Operating margin-4.6%
Net margin-6.8%
EBITDAUSD -150,004.00

Each USD of equity lost 14 cents this year.

Cash & shareholders

·
returned in FY2023 · dividends + net buybacks
Free cash flow $
FY2023 · FCF -125163.0
150000300000-200000-400000
201020162023
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 3.2M
EquityUSD 2.3M
Current ratio3.08×

Equity funds 71% of total assets.

The 14-year record

14 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
PCYN, 14-year financial record
Metric 20232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.00.00.00.00.00.0−0.0−0.00.0−0.00.00.0
EBITDA $B−0.0−0.0−0.00.00.00.00.00.0−0.0−0.00.00.00.00.0
Income tax $B0.0−0.0−0.00.00.00.00.00.00.00.0−0.00.00.00.0
Net income $B−0.0−0.0−0.00.00.00.0−0.00.00.0−0.00.0−0.00.00.0
Free cash flow $B−0.0−0.0−0.00.00.00.00.00.0−0.0−0.0−0.0−0.00.00.0
EPS, diluted $−0.04−0.01−0.030.080.010.00−0.030.000.01−0.030.00−0.020.010.02
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————
ROE %−13.9−1.9−7.627.55.31.3−11.80.55.0−9.61.0−4.35.48.3
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.010.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 67 reconciliationsAUDITED

Reconciled in 14 of the 14 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inColorado
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image